Phase 3 GiACTA Trial Results for TCZ in Giant Cell Arteritis
John H. Stone, MD, MPH, discusses results from a phase 3, double-blind, randomized, controlled trial evaluating the efficacy of tocilizumab for the treatment of giant cell arteritis.
Vasculitis
Reducing Glucocorticoid Exposure in ANCA-Associated Vasculitis
Researchers suggest that relapsing MPA and GPA and increased BMI were associated with increased glucocorticoid exposure following induction of remission.
New-Onset Diabetes Risk in Giant Cell Arteritis With Prednisone
Treatment of giant cell arteritis or granulomatosis with polyangiitis with prednisolone or prednisone has been linked to elevated risks of type 2 diabetes early during treatment.
Tocilizumab Granted Breakthrough Therapy Designation by FDA for GCA
Tocilizumab (Actemra®,Genentech) is the first treatment proposed for giant cell arthritis in 50 years.
Shared Etiologic Inflammatory Link in Pediatric KD, Adult KLS
Distinctive presentations, histopathology, and therapeutic response in both KD and KLS suggest a common etiology.
Incidence of VTE, Stroke in GCA and Non-GCA Comparators
Retrospectively acquired population-based data suggest that the incidence of VTE, stroke and TIA was similar in patients with GCA compared to those who did not have GCA.
Is Post-Vaccination IgG Predictive of Mortality in Systemic Vasculitis?
Low IgG and B cell counts were associated with infection and vaccine response among patients with systemic vasculitis in stable remission.
Lead Investigator Discusses Implications of the GiACTA Trial for GCA Treatment
Rheumatology Advisor speaks with John Stone, MD, MPH, Edward Fox Chair in Medicine at Massachusetts General Hospital who is the lead investigator of a phase III, double-blind, randomized trial evaluating the safety and efficacy of tocilizumab for giant cell arteritis
Biomarkers Prognostic of Immunosuppression Side Effects in Vasculitis
Measuring IgG levels and B cell counts may identify high infection risk and help clinicians balance the risk of immunosuppression side effects and disease activity in patients with systemic vasculitis.
Churg-Strauss Syndrome: ANCA Positivity and Long-Term Outcomes
Study assesses long-term outcomes associated with Churg-Strauss syndrome and provides insights on how to better care for these patients.
- Loading...
Loading...
Next post in General Rheumatology
Loading... 
Loading...